Our Pipeline of therapeutic candidates

CB-24

CROTOXIN

  • Nicotinic antagonist
  • Bipartite self-targeting drug anti-inflammatory
  • Targeting NSCLC & solid tumors
  • 2 parts of Phase I trial completed
PHASE I / II STUDY UNDER PREPARATION

CB-6

COBRAMINE

  • Protein kinase C inhibitor
  • Anti-inflammatory action
  • Orally bioavailable peptide
  • Targeting chronic kidney disease
PHASE I READY

CB-24/CB-6

CTC-310

  • Nicotinic antagonist / Protein kinase inhibitor combination
  • Anti-inflammatory
  • Clinical efficacy in Phase I study
  • Targeting pancreatic, colon & hematological Cancers
PHASE I / II STUDY UNDER PREPARATION

CB-4

CROTAMINE

  • Cell penetrating peptide
  • Orally bioavailable
  • Active against melanoma
  • Potential gene therapy applications
PRECLINICAL